Fluicell AB (publ) ("Fluicell" or the "Company") hereby announces that the Company is part of a collaboration that has received funding from Breakthrough T1D (formerly JDRF), the leading global type 1 diabetes research and advocacy organization, for the development of tissue-based implants for type 1 diabetes treatment. The funded project is a collaboration between Fluicell and a prominent diabetes researcher at a top ranked American medical university, and combines Fluicell's tissue platform Nexocyte with specially developed stem cell-based pancreatic cells. The project funding amount is up to USD 600K, and is shared equally by the project partners.
Fluicell's CEO Carolina Trkulja comments:
"This is a very significant day for Fluicell. Through the collaboration with an internationally prominent diabetes researcher at a top ranked American medical university, Fluicell is taking important steps forward in the development of our diabetes program. The fact that the collaboration is also supported by Breakthrough T1D is particularly gratifying. Fluicell’s goal with this collaboration is to create groundbreaking new treatment solutions for type 1 diabetes."
About Breakthrough T1D
As the leading global type 1 diabetes research and advocacy organization, Breakthrough T1D helps make everyday life with type 1 diabetes better while driving toward cures. They do this by investing in the most promising research, advocating for progress by working with government to address issues that impact the T1D community, and helping educate and empower individuals facing this condition. For more information, visit BreakthroughT1D.org.
For more information, please contact:
Carolina Trkulja, CEO
+46 (0) 705 52 63 25
About Fluicell
Fluicell is a life science company located in Mölndal, Sweden, which has commercialized a technology for processing and studying individual cells, primarily in drug development. Based on Fluicell's technology for constructing biological tissues with ultra-high detail, Fluicell is developing tissue-based therapies and screening models. The company's development work is mainly focused on tissue-based therapies for the treatment of type 1 diabetes and cardiac tissue models for drug screening. Fluicell's existing products are the tissue production platform Nexocyte,™ which is based on Biopixlar® and Biopixlar® AER, the Company's technologies for high-resolution bioprinting in both 2D and 3D. Fluicell's product portfolio also includes the research instruments BioPen®, Dynaflow® Resolve and Biozone 6®, which give researchers the opportunity to study, process and measure drug effects in individual cells at a unique level of detail. For more information, see www.fluicell.com